Joseph Pawluczyk - Concepedia

Author

Joseph Pawluczyk

United States Military Academy

Also Known As

J. M. PAWLUCZYK, J.M. Pawluczyk, Joseph M Pawluczyk, Joseph M. Pawluczyk, Joseph Pawluczyk, Pawluczyk, Joseph

Publications

680

Citations

H-Index

Concepts

All Affiliations

United States Military Academy Bristol-Myers Squibb (United States)Biocon (India)Bristol-Myers Squibb (India)

About

Joseph Pawluczyk is an author at United States Military Academy specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	265
2	Natural Sciences	5	5	231
3	Engineering	4	4	140
4	Biochemistry	4	4	208
5	Biomolecular Engineering	4	4	167

Joseph Pawluczyk

Publications

602

Citations

H-Index

Page 1

	Year	Citations
Synthesis of Cyclobutane-Fused Tetracyclic Scaffolds via Visible-Light Photocatalysis for Building Molecular Complexity Martins S. Oderinde, Edna Mao, Antonio Ramı́rez, Journal of the American Chemical Society	2020	144
Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity Martins S. Oderinde, Antonio Ramı́rez, T. G. Murali Dhar, The Journal of Organic Chemistry Combinatorial ChemistryEngineeringSynthetic PhotochemistryOrganic ChemistryChemistry	2020	78
Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-{4-[1-(2-Methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[<i>d</i>][1,3]oxazin-2-one (L-372,662) and Related Pyridines Ian M. Bell, Jill M. Erb, Roger Freidinger, Journal of Medicinal Chemistry PharmacotherapyOrally Active OxytocinExperimental PharmacologyPharmaceutical ChemistryOxytocin Antagonists	1998	60
1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. Bradley V. Clineschmidt, Jill M. Erb, Roger Freidinger, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryAltmetric Attention ScorePharmacotherapyPharmaceutical Chemistry	1995	56
Design and Synthesis of a Pro-Drug of Vinblastine Targeted at Treatment of Prostate Cancer with Enhanced Efficacy and Reduced Systemic Toxicity Stephen F. Brady, Joseph Pawluczyk, Patricia K. Lumma, Journal of Medicinal Chemistry Medicinal ChemistryUrologyOncologyDrug TargetingPolymer-drug Conjugate	2002	52
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Deborah Defeo-Jones, Stephen F. Brady, Dong-Mei Feng, PubMed Molecular PharmacologyUrologyOncologyEndocrine-related CancerGenitourinary Cancer	2002	43
Discovery of (<i>S</i>)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain Guanglin Luo, Ling Chen, Walter A. Kostich, Journal of Medicinal Chemistry	2022	27
Nanomolar-affinity, non-peptide oxytocin receptor antagonists B. Evans, G. F. Lundell, Kevin F. Gilbert, Journal of Medicinal Chemistry	1993	26
Microwave-initiated living free radical polymerization: optimization of the preparative scale synthesis of Rasta resins Joseph Pawluczyk, Ray T. McClain, Chris Denicola, Tetrahedron Letters Materials ScienceChemical EngineeringEngineeringPolymer TechnologyPolymer Science	2007	26
Intramolecular [2+2] Cycloaddition of N‐Allylcinnamamines and <i>N</i>‐Allylcinnamamides by Visible‐Light Photocatalysis Martins S. Oderinde, James Kempson, Daniel Smith, European Journal of Organic Chemistry EngineeringSynthetic PhotochemistryOrganic ChemistryChemistryCf 3	2019	26

Page 1